Clinical Trial News and Research

RSS

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.

8 May 2014

Research may have "major implications" for treatment of urinary tract infections in children

A major new pediatric research study led by a Wayne State University researcher, funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) and published this week in the New England Journal of Medicine (NEJM), has "major implications" for the treatment of urinary tract infections (UTIs) in millions of American children.

8 May 2014

Low-carbohydrate diet reduces inflammation in patients with type 2 diabetes

A low-carbohydrate diet, but not a low-fat diet, reduces inflammation in patients with type 2 diabetes, according to research at Linköping University in Sweden.

8 May 2014

Common drug may improve blood flow in muscles of boys with Duchenne muscular dystrophy

A drug typically prescribed for erectile dysfunction or increased pressure in the arteries may help improve blood flow in the muscles of boys with Duchenne muscular dystrophy, according to a study published in the May 7, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.

8 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2014.

7 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013.

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

Monthly injections to counteract AMD may not be necessary, say researchers

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary.

7 May 2014

Loxo Oncology announces closing of $24 million Series B private financing round

Loxo Oncology, Inc., a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced today that it has closed a $24 million Series B private financing round led by New Enterprise Associates.

6 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Attorney of Colson Hicks Eidson files wrongful death complaint on behalf of passenger killed on Macarthur Causeway

Attorney Ervin A. Gonzalez, partner at the Coral Gables-based law firm Colson Hicks Eidson, filed a wrongful death complaint in the 11th Judicial Circuit Court in Miami-Dade County on behalf of the family of the late Dr. Malcolm Lloyd, passenger in the Lamborghini that was involved in a fatal car crash on April 24th on MacArthur Causeway.

6 May 2014

New phase III clinical trial shows non-invasive focused ultrasound treatment relieves cancer pain

When cancer progresses and spreads to the bone, patients often suffer debilitating pain. Now, a new phase III clinical trial shows that non-invasive magnetic resonance guided focused ultrasound treatment that heats the cancer within the bone, relieves pain and improves function for most patients when other treatment options are limited.

6 May 2014

Young blood can rejuvenate brains of old mice

Something - or some things - in the blood of young mice has the ability to restore mental capabilities in old mice, a new study by Stanford University School of Medicine investigators has found.

6 May 2014

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.

6 May 2014

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer.

6 May 2014

Clinical Trial News and Research

Commonly used drug restores blood flow to oxygen-starved muscles of boys with muscular dystrophy

Research may have "major implications" for treatment of urinary tract infections in children

Low-carbohydrate diet reduces inflammation in patients with type 2 diabetes

Common drug may improve blood flow in muscles of boys with Duchenne muscular dystrophy

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ArQule reports net loss of $7,141,000 in first quarter 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Monthly injections to counteract AMD may not be necessary, say researchers

Loxo Oncology announces closing of $24 million Series B private financing round

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

FDA accepts Merck's MK-3475 BLA for review

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Attorney of Colson Hicks Eidson files wrongful death complaint on behalf of passenger killed on Macarthur Causeway

New phase III clinical trial shows non-invasive focused ultrasound treatment relieves cancer pain

Young blood can rejuvenate brains of old mice

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer